Suppr超能文献

流荧光显微镜成像技术对与严重不良反应相关的培格司亭制剂中超可见颗粒的特征具有敏感性。

Flow Microscopy Imaging Is Sensitive to Characteristics of Subvisible Particles in Peginesatide Formulations Associated With Severe Adverse Reactions.

机构信息

Center for Pharmaceutical Biotechnology, Department of Chemical and Biological Engineering, University of Colorado, Boulder, Colorado 80309-0596.

Center for Pharmaceutical Biotechnology, Department of Chemical and Biological Engineering, University of Colorado, Boulder, Colorado 80309-0596.

出版信息

J Pharm Sci. 2018 May;107(5):1313-1321. doi: 10.1016/j.xphs.2018.01.015. Epub 2018 Feb 1.

Abstract

The presence of subvisible particles in formulations of therapeutic proteins is a risk factor for adverse immune responses. Although the immunogenic potential of particulate contaminants likely depends on particle structural characteristics (e.g., composition, size, and shape), exact structure-immunogenicity relationships are unknown. Images recorded by flow imaging microscopy reflect information about particle morphology, but flow microscopy is typically used to determine only particle size distributions, neglecting information on particle morphological features that may be immunologically relevant. We recently developed computational techniques that utilize the Kullback-Leibler divergence and multidimensional scaling to compare the morphological properties of particles in sets of flow microscopy images. In the current work, we combined these techniques with expectation maximization cluster analyses and used them to compare flow imaging microscopy data sets that had been collected by the U.S. Food and Drug Administration after severe adverse drug reactions (including 7 fatalities) were observed in patients who had been administered some lots of peginesatide formulations. Flow microscopy images of particle populations found in the peginesatide lots associated with severe adverse reactions in patients were readily distinguishable from images of particles in lots where severe adverse reactions did not occur.

摘要

在治疗性蛋白质制剂中存在亚可见颗粒是引起不良反应的一个风险因素。虽然颗粒污染物的免疫原性潜力可能取决于颗粒的结构特征(例如组成、大小和形状),但确切的结构-免疫原性关系尚不清楚。流式成像显微镜记录的图像反映了颗粒形态的信息,但流式显微镜通常仅用于确定颗粒的粒径分布,而忽略了可能与免疫相关的颗粒形态特征的信息。我们最近开发了一些计算技术,利用 KL 散度和多维缩放来比较流式显微镜图像集中颗粒的形态特征。在目前的工作中,我们将这些技术与期望最大化聚类分析相结合,并将其用于比较美国食品和药物管理局在一些培格司亭制剂的患者中观察到严重药物不良反应(包括 7 例死亡)后收集的流式成像显微镜数据集。与患者严重不良反应相关的培格司亭制剂中发现的颗粒群体的流式显微镜图像很容易与严重不良反应未发生的批次中颗粒的图像区分开来。

相似文献

本文引用的文献

6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验